Agile Therapeutics Inc (AGRX)
0.3856
+0.02
(+4.10%)
USD |
OTCM |
Apr 16, 15:54
Agile Therapeutics Enterprise Value: 1.688M for April 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 15, 2024 | 1.688M |
| April 12, 2024 | 1.645M |
| April 11, 2024 | 2.030M |
| April 10, 2024 | 1.583M |
| April 09, 2024 | 1.678M |
| April 08, 2024 | 1.850M |
| April 05, 2024 | 1.137M |
| April 04, 2024 | 1.120M |
| April 03, 2024 | 1.068M |
| April 02, 2024 | 1.018M |
| April 01, 2024 | 1.000M |
| March 28, 2024 | 1.480M |
| March 27, 2024 | 1.686M |
| March 26, 2024 | 0.1389M |
| March 25, 2024 | 0.9337M |
| March 22, 2024 | 0.7698M |
| March 21, 2024 | 0.8116M |
| March 20, 2024 | 0.865M |
| March 19, 2024 | 0.7126M |
| March 18, 2024 | 0.8087M |
| March 15, 2024 | 0.7583M |
| March 14, 2024 | 0.9008M |
| March 13, 2024 | 1.241M |
| March 12, 2024 | 1.309M |
| March 11, 2024 | 1.277M |
| Date | Value |
|---|---|
| March 08, 2024 | 1.357M |
| March 07, 2024 | 1.416M |
| March 06, 2024 | 1.539M |
| March 05, 2024 | 1.579M |
| March 04, 2024 | 1.684M |
| March 01, 2024 | 1.668M |
| February 29, 2024 | 1.505M |
| February 28, 2024 | 1.427M |
| February 27, 2024 | 1.492M |
| February 26, 2024 | 1.544M |
| February 23, 2024 | 1.787M |
| February 22, 2024 | 1.957M |
| February 21, 2024 | 2.090M |
| February 20, 2024 | 2.261M |
| February 16, 2024 | 2.705M |
| February 15, 2024 | 2.772M |
| February 14, 2024 | 2.705M |
| February 13, 2024 | 2.705M |
| February 12, 2024 | 2.676M |
| February 09, 2024 | 2.617M |
| February 08, 2024 | 2.705M |
| February 07, 2024 | 2.942M |
| February 06, 2024 | 3.624M |
| February 05, 2024 | 3.387M |
| February 02, 2024 | 3.506M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.126M
Minimum
Jun 28 2023
281.65M
Maximum
Feb 16 2021
74.12M
Average
50.53M
Median
Oct 09 2019
Enterprise Value Benchmarks
| Altimmune Inc | 337.44M |
| iBio Inc | 16.59M |
| Ampio Pharmaceuticals Inc | -3.385M |
| Oragenics Inc | 3.888M |
| Actinium Pharmaceuticals Inc | 171.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.47M |
| Revenue (Quarterly) | 3.614M |
| Total Expenses (Quarterly) | 7.666M |
| EPS Diluted (Quarterly) | -1.41 |
| Gross Profit Margin (Quarterly) | 39.37% |
| Profit Margin (Quarterly) | -123.7% |
| Earnings Yield | -2.53K% |
| Normalized Earnings Yield | -3550.08 |